|
|||||
|
|

Aerospace and defense company Ducommun (NYSE:DCO) met Wall Streets revenue expectations in Q3 CY2025, with sales up 5.5% year on year to $212.6 million. Its non-GAAP profit of $0.99 per share was 3.9% above analysts’ consensus estimates.
Is now the time to buy DCO? Find out in our full research report (it’s free for active Edge members).
Ducommun’s third quarter results met Wall Street’s revenue expectations but prompted a negative market reaction, with investors focused on the company’s sharply lower operating margin due to a substantial litigation settlement. Management attributed the quarter’s top-line growth to continued strength in the defense segment, particularly missiles and radar programs, which offset declines in commercial aerospace. CEO Stephen Oswald acknowledged ongoing commercial aerospace destocking as a key headwind, explaining, “We achieved this despite continued headwinds in our commercial aerospace business, which has been previously forecasted due to destocking at BA and SPR.” Adjusted margins improved, but the one-time legal charge dominated GAAP profitability.
Looking forward, management’s guidance is shaped by expectations of robust defense demand and a gradual recovery in commercial aerospace, though the latter remains constrained by inventory corrections at key customers. The company’s strategy remains focused on expanding its engineered products portfolio and capturing new defense contracts. Oswald said, “We are positioned very well strategically to benefit from the replenishment of depleted worldwide inventories along with robust U.S. and FMS order activity.” Management also highlighted anticipated cost savings from facility consolidations and ongoing margin improvement as key drivers for the remainder of the year and into 2026.
Management attributed the quarter’s results to strength in defense programs, margin expansion from engineered products, and facility consolidation, while also noting the significant impact from the Guaymas Fire litigation settlement.
Ducommun’s outlook is anchored by sustained defense demand, facility cost savings, and a gradual recovery in commercial aerospace, though inventory headwinds are expected to persist.
In the coming quarters, the StockStory team will monitor (1) the pace of defense order growth, particularly from missile and radar programs; (2) signs of stabilization or improvement in commercial aerospace demand as destocking runs its course; and (3) realization of cost savings and margin expansion from facility consolidation efforts. Progress in shifting more revenue to engineered products and updates on the M&A pipeline will also be key indicators of strategic execution.
Ducommun currently trades at $92.28, in line with $92.12 just before the earnings. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it’s free for active Edge members).
Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.
Take advantage of the rebound by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
| Nov-10 | |
| Nov-06 | |
| Nov-06 | |
| Nov-06 | |
| Nov-06 | |
| Nov-06 | |
| Nov-04 | |
| Nov-04 | |
| Nov-04 | |
| Oct-30 | |
| Oct-23 | |
| Oct-09 | |
| Sep-19 | |
| Sep-15 | |
| Sep-14 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite